CAR-T THERAPY
EXPLAINED
A complete guide to chimeric antigen receptor T-cell therapy โ one of the most transformative advances in cancer treatment for blood cancers.
analyticsAt a Glance
- check_circleCAR-T stands for Chimeric Antigen Receptor T-cell therapy
- check_circlePatient's own T-cells are extracted, engineered in a lab, and reinfused to attack cancer
- check_circleThe process takes 3โ6 weeks from leukapheresis (cell collection) to infusion
- check_circleMost approved for blood cancers; solid tumour trials are rapidly expanding
What Is CAR-T Cell Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalized cancer treatment that reprograms a patient's own immune cells to recognize and destroy cancer. T-cells are extracted, genetically modified in a lab to express a synthetic receptor, then infused back into the patient.
โCAR-T therapy turns a patient's own immune cells into precision-guided cancer fighters.โ
How CAR-T Therapy Works
The CAR-T process involves several critical steps from cell collection to infusion.
- 1
Eligibility Assessment
Oncologist evaluates cancer type, prior treatments, and organ function.
- 2
Leukapheresis
T-cells are collected from the patient's blood via apheresis.
- 3
CAR-T Manufacturing
T-cells are genetically modified with the CAR construct in a specialized lab.
- 4
Lymphodepletion Chemotherapy
Short course of chemo to prepare the body for CAR-T cell engraftment.
- 5
CAR-T Infusion
Modified T-cells infused into the patient. Monitoring begins immediately.
- 6
Recovery & Monitoring
Hospital stay for CRS/ICANS monitoring, then outpatient follow-up.
FDA-Approved CAR-T Products
Currently approved CAR-T therapies for clinical use.
| Product | Target | Indication | Key Efficacy |
|---|---|---|---|
| Kymriah (tisagenlecleucel) | CD19 | r/r B-ALL (pediatric/YA), r/r DLBCL | 81% CR in B-ALL |
| Yescarta (axi-cel) | CD19 | r/r LBCL, 2L+ LBCL | 83% ORR in LBCL |
| Tecartus (brexu-cel) | CD19 | r/r MCL, r/r B-ALL (adult) | 91% ORR in MCL |
| Breyanzi (liso-cel) | CD19 | r/r LBCL (2L+) | 73% ORR |
| Abecma (ide-cel) | BCMA | r/r multiple myeloma | 73% ORR |
| Carvykti (cilta-cel) | BCMA | r/r multiple myeloma | 97.9% ORR |
CAR-T Benefits vs Risks
Benefits
- High remission ratesUp to 90%+ in certain blood cancers.
- Single infusion treatmentOne-time therapy rather than ongoing cycles.
- Durable responsesMany patients maintain remission for years.
Risks
- Cytokine Release Syndrome (CRS)Fever, hypotension, organ dysfunction. Managed with tocilizumab.
- ICANS (neurotoxicity)Confusion, seizures. Managed with corticosteroids.
- Prolonged cytopeniasLow blood counts requiring monitoring.
CAR-T by the Numbers
- 6FDA-approved products
- 97.9%Highest ORR (Carvykti)
- $80K-$475KCost range (China to US)
- 30,000+Patients treated globally
Frequently Asked Questions
About CAR-T Therapy
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Considering CAR-T Therapy for Your Cancer?
Upload your medical reports for a free evaluation. Our team connects patients with CAR-T centers in the US, EU, and China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.